

1 **Sealing Behaviour in Transcatheter Bicuspid and Tricuspid Aortic Valves Replacement**
2 **through Patient-Specific Computational Modeling**

3
4 Xian-Bao Liu, MD, PhD^{§a,b}, Jia-Qi Fan, MD^{§a}, Peter Mortier, MSc, PhD^c, Yu-Xin He, MD^a,
5 Qi-Feng Zhu, MD^a, Yu-Chao Guo, MD^a, Xin-Ping Lin, MD^a, Hua-Jun Li, MD^a, Ju-Bo Jiang,
6 MD^a, Giorgia Rocatello, MSc, PhD^c, Vanda Oliveira, MSc^c, Tim Dezutter, MSc^c, Lars
7 Sondergaard, MD, DMSc^d, Jian-An Wang, MD, PhD^{a,b*}

8
9 ^aDepartment of Cardiology, Second Affiliated Hospital Zhejiang University School of
10 Medicine, Hangzhou, People's Republic of China

11 ^bZhejiang University School of Medicine, Hangzhou, People's Republic of China

12 ^cFEops, Ghent, Belgium

13 ^dDepartment of Cardiology, Rigshospitalet, Copenhagen, Denmark

14

15 **Short Title:** Sealing behaviour in BAV and TAV TAVR patients

16

17 **Total Word Count:**

18 Manuscript - 3000

19

20 **Address for Correspondence:**

21 Jian'an Wang, MD, PhD

22 *Corresponding author: Tel +86-571-87783992; fax +86-571-87037885

23 E-mail address: wangjianan111@zju.edu.cn (J. Wang).

24 Mailing address: Department of Cardiology, Second Affiliated Hospital, Zhejiang University

25 School of Medicine, Hangzhou 310009, China.

26 §Drs Liu and Fan contributed equally to the manuscript.

27

28

1 **ABSTRACT**

2 **BACKGROUND:** Patient-specific computer simulation of transcatheter aortic valve
3 replacement (TAVR) can provide unique insights in device-patient interaction. The aim of
4 this study was to compare transcatheter aortic valve sealing behaviour in patients with
5 bicuspid aortic valves (BAV) and tricuspid aortic valves (TAV) through patient-specific
6 computational modeling.

7 **METHODS:** Patient-specific computer simulation was retrospectively performed with
8 FEops HEARTguide for patients who underwent TAVR using the Venus A-
9 Valve. Simulation output was compared with postprocedural computed tomography and
10 echocardiography to validate the accuracy of the simulation. Sealing behaviour was analysed
11 based on the predicted device-patient interaction by quantifying the distance between the
12 transcatheter heart valve (THV) skirt and the surrounding anatomical regions. Skirt
13 malapposition was defined by a distance larger than 1mm.

14 **RESULTS:** In total, 43 patients were included in the study. Predicted and observed THV
15 frame deformation showed good correlation ($R^2 \geq 0.90$) for all analysed measurements
16 (maximum diameter, minimum diameter, area and perimeter). The amount of predicted THV
17 skirt malapposition was strongly linked with the echocardiographic grading of paravalvular
18 leakage (PVL). More THV skirt malapposition was observed for BAV cases when compared
19 to TAV cases (22.7% vs 15.5%, $p < 0.05$). A detailed analysis of skirt malapposition showed
20 a higher degree of malapposition in the interleaflet triangles section for BAV cases as
21 compared to TAV patients (11.1% vs 5.8%, $p < 0.05$).

22 **CONCLUSIONS:** Patient-specific computer simulation of TAVR can accurately predict the
23 behaviour of the self-expanding Venus A-Valve. BAV patients are associated with more
24 malapposition of the THV skirt as compared to TAV patients, and this is mainly driven by
25 more malapposition in the interleaflet triangle region.

26 **Key Words:** Transcatheter aortic valve replacement, bicuspid aortic valve, patient-specific
27 computational modeling, sealing behaviour.

1 **Key messages**

2 **What is already known on this subject?**

3 Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV)
4 is becoming increasingly important due to expanding indications towards younger patients, as
5 well as to geographic growth of the therapy. Patient-specific computational modeling of
6 TAVR based on pre-procedural computed tomography (CT) has emerged as a promising
7 technology capable of accurately predicting device-anatomy interaction, as well as
8 paravalvular leakage and the risk on TAVR-induced conduction abnormalities for both
9 tricuspid aortic valve (TAV) and BAV patients.

10

11 **What might this study add?**

12 BAV patients are associated with more malapposition of the transcatheter heart valve (THV)
13 skirt as compared to TAV patients, and this is mainly driven by more malapposition in the
14 interleaflet triangle region. More cases and studies are needed to confirm the results and
15 related malapposition of the THV skirt to clinical echo-based paravalvular leakage grading.

16

17 **How might this impact on clinical practice?**

18 Patient-specific computational modeling of TAVR based on pre-procedural CT might be
19 performed in BAV patients. Transcatheter heart valve size and ideal implanted depth could be
20 recommended to reduce the malapposition and potential paravalvular leakage.

21

- 1 **Nonstandard Abbreviations and Acronyms**
- 2 AS = aortic stenosis
- 3 BAV = bicuspid aortic valve
- 4 CAD = computer aided design
- 5 CT = computed tomography
- 6 FEA = finite element analysis
- 7 HU = Hounsfield unit
- 8 DSCT = dual source computed tomography
- 9 TAV = tricuspid aortic valve
- 10 TAVR = transcatheter aortic valve replacement
- 11 TTE = transthoracic echocardiography
- 12

1 **Introduction**

2 Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV)
3 is becoming increasingly important due to expanding indications which include younger
4 patients, as well as to global adoption. In many countries, TAVR has become the standard of
5 care for high risk patients, and is now expanding into younger, lower risk patients, resulting
6 in an increased amount of patients with BAV stenosis [1–4]. On the other hand, the Chinese
7 TAVR market is still relatively small but growing rapidly, and the prevalence of BAV cases
8 in China is notably higher than in other countries [5]. Several clinical studies have
9 demonstrated the safety and efficacy of TAVR in BAV patients [3,4], but there are still
10 several challenges when treating BAV stenosis and patients should be carefully selected.
11 Therefore, efforts to increase our knowledge of how TAVR devices interact with BAVs
12 remain important.

13

14 The interaction of transcatheter heart valves with the aortic root is likely to be different
15 between BAV and tricuspid aortic valve (TAV) patients. While device sizing for TAV cases
16 is mainly based on the dimensions of the aortic annulus, an assessment of the supra-annular
17 structure seems mandatory for BAV cases as this can be the primary location where the THV
18 interacts with the aortic root [6,7]. This, however, depends on several anatomical factors such
19 as BAV type, calcium burden, raphe length and the ratio of the intercommissural diameter to
20 the mean annular diameter [7].

21

22 Patient-specific computational modeling of TAVR with FEops HEARTguide (FEops, Ghent,
23 Belgium) based on pre-procedural computed tomography (CT) has emerged as a promising
24 technology capable of accurately predicting device-anatomy interaction, as well as
25 paravalvular leakage and the risk on TAVR-induced conduction abnormalities for both TAV
26 and BAV patients [8–12]. Validation data is mainly available for the Medtronic self-
27 expanding and the Boston Scientific mechanically expandable THVs. These three-
28 dimensional computer models provide detailed insights that cannot be obtained through post-
29 procedural imaging, and may also help to better understand the sealing behaviour in BAV
30 and TAV patients.

31

32 In this study, we aimed to validate a patient-specific computer simulation of TAVR in
33 Chinese patients treated with the self-expandable Venus-A valve and use the validated

1 computational model to explore potential differences in the sealing behaviour between BAV
2 and TAV patients.

3
4

5 **Methods**

6

7 A retrospective single-centre study was performed on patients who underwent transcatheter
8 aortic valve replacement using a Venus A-Valve (Venus Medtech). Both pre- and post-
9 procedural CT imaging was available for all patients. All dual source computed tomography
10 (DSCT) examinations were performed with the second generation dual-source CT
11 (SOMATOM Definition Flash, Siemens Medical Solutions, Germany). The scan area was
12 craniocaudal from the subclavian artery to the iliofemoral branches. Prospective ECG gating
13 with a pitch of 2.4 was performed. Around 60–80 ml of iodine-containing contrast agent
14 (Omnipaque 370 mg I/ml, GE Healthcare, Shanghai, China) was injected with a dual head
15 power injector (Mallinckrodt, American) at a flow rate of 4 ml/s followed by 60 ml 0.9%
16 saline solution at the same flow rate. A bolus tracking method was used in the descending
17 aorta with a pre-set threshold of 180 Hounsfield Units (HU) to achieve optimal
18 synchronization. The tube voltage was 100 kV, with a reference tube current-time product of
19 280 mAs and a collimation of 38.4 mm (2*32*0.6 mm³) with double sampling by z-axis
20 flying focal spot. All procedures were performed as reported in previous studies [13,14]. The
21 study was approved by the medical ethics committee of Second Affiliated Hospital of
22 Zhejiang University and carried out according to the principles of the Declaration of Helsinki.
23 All patients provided written informed consent for TAVR and the use of anonymous clinical,
24 procedural, and follow-up data for research.

25

26 **Virtual Device Modeling**

27 Accurate finite element models of the frames of all Venus A-Valve sizes (23, 26, 29 and
28 32mm) were generated based on CAD (Computer Aided Design) data provided by the device
29 manufacturer. A virtual radial force test was performed to validate the virtual device models
30 using the finite element analysis (FEA) software Abaqus (Abaqus v6.12, Dassault Systèmes,
31 Paris, France). For this test, the device was crimped to a smaller diameter (loading) and then
32 released (unloading) while the radial force in the crimper was measured. The model radial
33 force was then compared with the experimental radial force data during unloading and within

1 the relevant deployment range for each valve size. Model parameters were calibrated until
2 excellent agreement was obtained.

3

4 **Patient-specific Computational Modeling**

5 Three-dimensional patient-specific geometries of the native aortic root (including the
6 calcified native leaflets) were reconstructed from pre-operative contrast-enhanced CT scans,
7 using the image segmentation software Mimics (Mimics v21.0, Materialise, Leuven,
8 Belgium). Venus A-valve models were then virtually deployed in these geometries using
9 Abaqus. These simulations allow to assess the device, native leaflet and aortic wall
10 deformation as previously described [8,10,11]. For each simulated implantation, the valve
11 size selection and the depth of implantation were aligned with the clinical procedure. The
12 simulated depth of implantation was iteratively adjusted to match the actual depth of
13 implantation derived from the post-operative geometry, which was reconstructed from post-
14 operative CT images using Mimics. This was done by overlaying the simulation results with
15 the post-operative geometry using a manual geometrical registration method. An overview of
16 these different reconstruction and modeling steps is summarized in Figure 1.

17

18 **Frame deformation comparison**

19 For each patient, predicted frame deformation was both qualitatively and quantitatively
20 compared to the post-operative device deformation (CT). A visual inspection was performed
21 by overlaying the predicted and post-operative devices and their dimensions (minimum and
22 maximum diameter, perimeter and area) were quantified at four relevant device levels:
23 commissures, central coaptation, nadir and ventricular end [8].

24

25 **Sealing analysis**

26 The regions of skirt apposition and malapposition were determined for all patients using the
27 predicted device and aortic root deformation. Apposition was considered when the deformed
28 device skirt is in contact with the anatomy, while malapposition when the opposite is verified.
29 The areas corresponding to the apposed and malapposed skirt were quantified in four
30 different regions of the aortic root anatomy: left ventricular outflow tract (LVOT), leaflets,
31 interleaflet triangles, and ascending aorta.

32

33 In order to obtain these regions, the deformation anatomy (after simulated device
34 deployment) was firstly divided into the anatomical sections mentioned above. Then, each

1 element of the simulated skirt was attributed to one of these anatomical regions and the
2 distance between the skirt and the anatomy was calculated. This was done by searching the
3 anatomy element in the normal direction to each skirt element. Apposition and malapposition
4 were then attributed to each element based on the distance (apposed if distance smaller than
5 1mm, malapposed otherwise). Finally, the skirt was projected in 2D and the apposed and
6 malapposed areas computed for each anatomical section. A visual overview of the separation
7 of the skirt into sections (both anatomical and apposition) is shown in Figure 2. The obtained
8 area values were grouped according to the aortic valve morphology: tricuspid (TAV),
9 bicuspid (all types, BAV), bicuspid type 0 (BAV0) and BAV type 1 (BAV1) using the
10 Sievers classification [15].

11

12 PVL comparison

13 Transthoracic Doppler echocardiography was used for the clinical PVL assessment. PVL was
14 classified as none or trace, mild, or moderate based on the VARC-2 criteria. Observed PVL
15 grades were compared to the predicted amount of skirt malapposition. The grades were also
16 divided per valve morphology to detect possible patterns between the PVL severity and valve
17 morphology.

18

19 Statistical Analysis

20 Continuous variables are expressed as mean±SD. Correlation between predicted and
21 observed continuous variables was analysed using the coefficient of determination (R^2).
22 Difference plots were constructed according to the Bland-Altman method. Comparisons
23 within the sealing analysis were carried out using the paired Student t test or Mann–Whitney
24 U test depending on the variable distribution. Baseline characteristics and anatomic
25 parameters were analysed to explore the association with malapposition in interleaflet
26 triangles. Only variables yielding a p value < 0.1 were included in the stepwise multivariate
27 linear regression analysis. Statistical significance was defined as a two-tailed p < 0.05.
28 Statistical analysis was performed with SciPy Stats, a Python module for probability
29 functions and statistical distributions.

30

31

32

33

1 **Results**

2

3 A total of 43 patients were included in the study. There was no significant difference in age
4 between BAV and TAV patients (BAV: 76.4 ± 7.1 years old vs. TAV: 79.4 ± 6.2 years old, $p =$
5 0.164) or other baseline characteristics, Table 1. Of these 43 patients, 26 patients were BAV
6 patients with 11 patients were type 0 and 15 were type 1. For the BAV patients, the sizing
7 index (ratio of device size to perimeter derived diameter) was lower when compared with
8 TAV patients (BAV: 1.04 ± 0.09 vs. TAV: 1.11 ± 0.07 , $p = 0.018$).

9

10 Comparison of Observed and Predicted Parameters

11 The mean differences and coefficients of determination between the measurements extracted
12 from the post-operative and simulated device are summarized in Table 2. This is presented
13 for each type of measurement for all levels of the device combined. A high coefficient of
14 determination was obtained for all measurements (≥ 0.90). All dimensions were slightly
15 underestimated by the model, but the mean differences are negligible. Correlation and
16 difference plots for each type of measurement are presented in Figure 3a and Figure 3b.

17

18 Echocardiography showed none or trace post-operative PVL in 13 patients, mild PVL in 24
19 and moderate PVL in 6. Figure 4 shows a comparison of predicted skirt malapposition for
20 patients with none to trace, mild and moderate PVL. The amount of skirt malapposition is
21 higher for patients with a higher degree of clinically assessed PVL (Supplementary Table 1).

22 A comparison of post-operative PVL assessment for patients with different valve
23 morphologies is shown in Figure 5. Moderate PVL was more frequent for BAV cases (19.2%
24 vs TAV 5.9%), with BAV0 having the highest incidence of moderate PVL (27.3% for BAV0
25 vs 13.3% for BAV1, respectively).

26

27 Comparison of sealing behaviour

28 A representative TAV (total skirt malapposition of 4.4%, no PVL) and BAV1 (total skirt
29 malapposition of 20.9%, mild PVL) case are depicted in Figure 6. A cross-section of the pre-
30 operative CT scan at the aortic annular plane and a 3D reconstruction illustrate the
31 morphology of the valves. For each valve, the 2D skirt is also shown with the apposition
32 borders highlighted, evidencing the larger area of malapposition in the BAV1 case (relatively
33 to TAV). For the BAV1 case, PVL channels are visible in the interleaflet triangles region.

34

1 An overview of all sealing analysis data for each valve morphology is provided in Table 3.
2 The mean percentage of total malapposed skirt obtained for each anatomical section (LVOT,
3 interleaflet triangles and leaflets) relatively to the total skirt is illustrated as bar plots for the
4 different valve morphologies in Figure 7a. In this analysis, the values obtained for the
5 ascending aorta section were not considered to simplify the analysis. More malapposition was
6 obtained for BAV cases when compared to TAV cases (22.7 vs 15.5%, $p < 0.05$), and this is
7 also true when comparing TAV cases to BAV type 0 and BAV type 1 cases separately. This
8 seems mainly driven by a higher degree of malapposition in the interleaflet triangles section:
9 5.8% and 11.1% for TAV and BAV ($p < 0.05$), respectively.

10

11 The percentage of apposed skirt obtained out of the apposed section of the total skirt is
12 illustrated as pie charts for each anatomical section and valve morphology in Figure 7b.
13 There is a trend for a higher contribution of the left ventricular outflow tract (LVOT) to the
14 apposition in TAV (17.0%) as compared to BAV cases (11.7%), and this difference is most
15 pronounced for BAV type 0 patients (8.4%). In contrast, the leaflets seem to contribute more
16 to apposition in BAV (73.6%) than in TAV cases (64.8%), and this is also true when looking
17 at BAV type 0 and type 1 separately. However, no statistical significance was observed for
18 these comparisons.

19

20 The multivariate linear regression analysis identified that BAV ($p = 0.009$) and sizing index
21 ($p = 0.034$) as two independent predictors of malapposition in interleaflet triangles. The
22 results of univariate and multivariate linear regression for association with malapposition in
23 interleaflet triangles are presented in Supplementary Table 2.

24

1 **Discussion**

2 In this study, we evaluated a patient-specific computer model of TAVR in Chinese BAV and
3 TAV patients with the self-expanding Venus A-Valve using FEops HEARTguide (FEops,
4 Ghent, Belgium). We compared the predicted THV frame deformation with postprocedural
5 CT and found excellent correlation. Moreover, we observed a good agreement between
6 predicted THV skirt malapposition and postoperative PVL based on echocardiography.
7 Finally, we conducted a detailed sealing analysis and found that more malapposition was
8 obtained in BAV patients when compared to TAV patients which was mainly driven by more
9 malapposition at the location of the interleaflet triangles. Interestingly, the leaflets seem to be
10 the main contributor to device sealing (apposition) not only in BAV but also in TAV cases.

11 **Validation of the modeling**

12 Patient-specific computer simulation of TAVR has been previously described and validated,
13 not only in TAV patients but also in BAV cases (FEops, Ghent, Belgium) [8–12]. These
14 previous studies showed that computer simulation can accurately predict the THV frame
15 deformation, severity of PVL, and potential occurrence of conduction abnormalities.
16 However, these studies primarily focused on the Medtronic self-expanding and the Boston
17 Scientific mechanically expandable THVs, and were all conducted by European hospitals. In
18 this study, we employed the patient-specific computer simulation for the first time in a
19 Chinese patient population with the self-expanding Venus A-Valve. Despite the higher radial
20 force of the Venus A-Valve and the high calcium burden in this Chinese population, an
21 excellent agreement between the predicted and observed dimensions of the valve frame was
22 obtained [5,16]. Moreover, we compared predicted THV skirt malapposition and clinically
23 assessed PVL, and found a good relationship.

24 These validated patient-specific computer simulations may help clinicians to better
25 understand the risk of the procedure, and to optimize device sizing and positioning for each
26 individual. This useful tool can also assist physicians recognizing patients who would benefit
27 from TAVR and other patients for whom SAVR may be the preferred treatment. TAVR in
28 mainland China is rapidly evolving, and the most widely used commercial THV is currently
29 the Venus A-Valve [17,18]. Therefore, the presented study may be an important step to bring
30 this technology to the Chinese physicians.

31 **Sealing behavior in BAV and TAV patients**

32 TAVR in BAV patients has proven to be safe and effective, but patients need to be selected
33 carefully and a widely accepted THV sizing strategy is still lacking. One key challenge of
34 BAV disease is the increased anatomical heterogeneity as compared to TAV disease. In

1 addition, there are important ethnic differences. In European populations, BAV type 1 with
2 L-R coronary cusp fusion is most common, while in Asian populations, an unexpected high
3 prevalence of type 0 was found [19,20]. As the deformed device skirt mainly interacts with
4 three different regions of the aortic root anatomy, LVOT, leaflets, and interleaflet triangles,
5 we performed a detailed analysis of the sealing behavior in these anatomical regions in BAV
6 and TAV patients.

7 In the presented study, we found more malapposition in BAV patients when compared to
8 TAV patients which was mainly driven by more malapposition in the interleaflet triangles. It
9 should be emphasized that the pathologic landmark of BAV is always an absent or
10 underdeveloped interleaflet triangle: a dysmorphic, underdeveloped interleaflet triangle is
11 usually accompanied by a raphe, while the type 0 BAV is a valve with complete absence of
12 one interleaflet triangle [21]. Another factor is that TAVR in BAV might result in uneven
13 bioprosthetic valve frame expansion after THV deployment, and the deformed device (skirt)
14 may not touch the interleaflet triangle under the restricted stent-frame expansion [19,22–24].
15 This may explain the higher amount of malapposition that we observed in the interleaflet
16 triangle region in type 0 and type 1 BAV cases compared with TAV.

17 Another finding is that the leaflets seem to be the main contributor to device sealing, not only
18 in BAV but also in TAV cases. The importance of the interaction between the supra annular
19 structure and THV has already been discussed in previous studies [7,14,25–27]. Our present
20 study based on patient-specific computer simulation further clarifies the crucial contribution
21 of the leaflets to the supra-annular sealing. Overall, these results confirm that an assessment
22 of the supra-annular structure is important for the adequate planning of TAVR in BAV cases.
23 Moreover, in our present study, we found a trend for a higher contribution of the LVOT to
24 the apposition in TAV as compared to BAV cases, and this difference is most pronounced for
25 BAV type 0 patients. This result may be partially explained by the depth of implantation. As
26 described in the baseline characteristics, BAV type 0 patients had a tendency of higher
27 implantation than TAV. In addition, for BAV type 0 patients, the fish mouth like shape of the
28 valve may result in an under expansion of the THV frame in the annular and sub-annular
29 (LVOT) region, and thus reduce the device-tissue interaction in this region.

30 **Malapposition and PVL**

31 The presented sealing analysis based on computational modeling may reflect the risk of PVL
32 after TAVR. As showed in Figure 4, a higher amount of malapposition section seems related
33 to the echo-based PVL grading. In addition, we observed a higher prevalence of moderate
34 echocardiographic identified PVL in the BAV group which might be explained by the

1 observed difference in sealing behavior between BAV and TAV cases. Understanding the
2 sealing behavior of TAVR in BAV and TAV patients could assist physicians to
3 comprehensively assess the risk of PVL and evaluate the interaction between supra-annular
4 structure and THV stent frame.

5 **Limitations**

6 This study was a small and retrospective single-center study. Due to the low number of
7 patients with more than moderate PVL, no formal statistical analysis was performed. As a
8 retrospective study, the transthoracic echocardiography was used to assess the clinical PVL
9 and the location of PVL can't be evaluated for the limitation of imaging quality.

10

11 **Conclusions**

12 Patient-specific computer simulation of TAVR can be used in Chinese patients with the self-
13 expanding Venus A-Valve. Transcatheter aortic valve sealing behavior is different between
14 BAV and TAV patients with more malapposition at the location of the interleaflet triangles
15 section for BAV cases.

16

17 **Contributors** J-AW, X-BL, and J-QF design the study. X-BL, J-QF, Y-XH, Q-FZ, Y-CG, X-
18 PL, H-JL, and J-BJ conducted the study and performed the examinations. PM, GR, VO, TD,
19 and J-QF performed the patient-specific computer simulation and statistical analysis. J-QF
20 and PM performed the statistical analysis and wrote the manuscript. J-AW, LS, and PM
21 revised the manuscript. All authors have read and approved the final version of the
22 manuscript.

23 **Funding** This research project was partially funded by Venus Medtech.

24 **Competing interests** None declared.

25 **Patient and public involvement** Patients and/or the public were not involved in the design,
26 conduct, reporting or dissemination plans of this research.

27 **Relationship with Industry** GR, TD and VO are employees of FEops NV. PM is co-founder
28 of FEops NV. All other authors declare that there is no conflict of interest relevant to the
29 submitted work.

30

1 REFERENCES

- 2 1 Popma JJ, Deeb GM, Yakubov SJ, *et al.* Transcatheter Aortic-Valve Replacement with
3 a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med* 2019;**380**:1706–15.
- 4 2 Mack MJ, Leon MB, Thourani VH, *et al.* Transcatheter Aortic-Valve Replacement
5 with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med*
6 2019;**380**:1695–705.
- 7 3 Makkar RR, Yoon S-H, Leon MB, *et al.* Association Between Transcatheter Aortic
8 Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke.
9 *JAMA* 2019;**321**:2193–202.
- 10 4 Yoon S, Bleiziffer S, Backer O De, *et al.* Outcomes in Transcatheter Aortic Valve
11 Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis. *J Am Coll Cardiol*
12 2017;**69**:2579–89.
- 13 5 Jilaihawi H, Wu Y, Yang Y, *et al.* Morphological characteristics of severe aortic
14 stenosis in China: Imaging corelab observations from the first Chinese transcatheter
15 aortic valve trial. *Catheter Cardiovasc Interv* 2015;**85**:752–61.
- 16 6 Fan J, Fang X, Liu C, *et al.* Brain Injury After Transcatheter Replacement of Bicuspid
17 Versus Tricuspid Aortic Valves. *J Am Coll Cardiol* 2020;**76**:2579–90.
- 18 7 Tchetché D, De Biase C, Van Gils L, *et al.* Bicuspid aortic valve anatomy and
19 relationship with devices: The Bavard multicenter Registry: A European picture of
20 contemporary multidetector computed tomography sizing for bicuspid valves. *Circ*
21 *Cardiovasc Interv* 2019;**12**:1–10.
- 22 8 Schultz C, Rodriguez-Olivares R, Bosmans J, *et al.* Patient-specific image-based
23 computer simulation for the prediction of valve morphology and calcium displacement
24 after TAVI with the Medtronic CoreValve and the Edwards SAPIEN valve.
25 *EuroIntervention* 2016;**11**:1044–52.
- 26 9 De Jaegere P, De Santis G, Rodriguez-Olivares R, *et al.* Patient-Specific Computer
27 Modeling to Predict Aortic Regurgitation after Transcatheter Aortic Valve
28 Replacement. *JACC Cardiovasc. Interv.* 2016;**9**:508–12.
- 29 10 Rocatello G, El Faquir N, De Santis G, *et al.* Patient-Specific Computer Simulation to
30 Elucidate the Role of Contact Pressure in the Development of New Conduction
31 Abnormalities after Catheter-Based Implantation of a Self-Expanding Aortic Valve.
32 *Circ Cardiovasc Interv* 2018;**11**.

- 1 11 Dowling C, Bavo AM, El Faquir N, *et al.* Patient-Specific Computer Simulation of
2 Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Morphology. *Circ*
3 *Cardiovasc Imaging* 2019;**12**:1–10.
- 4 12 Dowling C, Firoozi S, Brecker SJ. First-in-Human Experience With Patient-Specific
5 Computer Simulation of TAVR in Bicuspid Aortic Valve Morphology. *JACC*
6 *Cardiovasc Interv* 2020;**13**:184–92.
- 7 13 Liu X bao, Jiang J bo, Zhou Q jing, *et al.* Evaluation of the safety and efficacy of
8 transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic
9 valve in a Chinese population. *J Zhejiang Univ Sci B* 2015;**16**:208–14.
- 10 14 Liu X, He Y, Zhu Q, *et al.* Supra-annular structure assessment for self-expanding
11 transcatheter heart valve size selection in patients with bicuspid aortic valve. *Catheter*
12 *Cardiovasc Interv* 2018;**91**:986–94.
- 13 15 Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from
14 304 surgical specimens. *J Thorac Cardiovasc Surg* 2007;**133**:1226–33.
- 15 16 Liao YB, Zhao ZG, Wei X, *et al.* Transcatheter aortic valve implantation with the self-
16 expandable venus A-Valve and CoreValve devices: Preliminary Experiences in China.
17 *Catheter Cardiovasc Interv* 2017;**89**:528–33.
- 18 17 Song G, Pan W, Zhou D, *et al.* 2019 China Structure Week: A novel 5G internet-based
19 training course for Structural Heart Disease is presented from China. *Eur Heart J*
20 2020;**41**:1325–7.
- 21 18 Hon JKF, Tay E. Transcatheter aortic valve implantation in Asia. *Ann Cardiothorac*
22 *Surg* 2017;**6**:504–9.
- 23 19 Jilaihawi H, Chen M, Webb J, *et al.* A Bicuspid Aortic Valve Imaging Classification
24 for the TAVR Era A Bicuspid Aortic Valve Imaging Classi fi cation for the TAVR
25 Era. *JACC Cardiovasc Imaging* 2017;**9**:1145–58.
- 26 20 Kong WKF, Delgado V, Poh KK, *et al.* Prognostic Implications of Raphe in Bicuspid
27 Aortic Valve Anatomy. *JAMA Cardiol* 2017;**2**:285. doi:10.1001/jamacardio.2016.5228
- 28 21 Amoretti F, Cerillo AG, Mariani M, *et al.* A simple method to visualize the bicuspid
29 aortic valve pathology by cardiac computed tomography. *J Cardiovasc Comput*
30 *Tomogr* 2020;**14**:195–8.
- 31 22 Rahhab Z, El Faquir N, Tchetché D, *et al.* Expanding the indications for transcatheter
32 aortic valve implantation. *Nat Rev Cardiol* 2020;**17**:75–84.
- 33 23 Rotman OM, Bianchi M, Ghosh RP, *et al.* Principles of TAVR valve design,
34 modelling, and testing. *Expert Rev Med Devices* 2018;**15**:771–91.

- 1 24 Kamioka N, Lederman RJ, Khan JM, *et al.* BI-SILICA During Transcatheter Aortic
2 Valve Replacement for Noncalcific Aortic Insufficiency. *JACC Cardiovasc Interv*
3 2018;**11**:2237–9.
- 4 25 Xiong TY, Li YJ, Feng Y, *et al.* Understanding the Interaction Between Transcatheter
5 Aortic Valve Prostheses and Supra-Annular Structures From Post-Implant Stent
6 Geometry. *JACC Cardiovasc Interv* 2019;**12**:1164–71.
- 7 26 Jeger R, Reuthebuch O, Fahrni G, *et al.* Supra-annular sizing for transcatheter valve
8 implantation in bicuspid aortic stenosis. *Postep w Kardiol Interwencyjnej*
9 2018;**14**:187–90.
- 10 27 Iannopollo G, Romano V, Buzzatti N, *et al.* A novel supra-annular plane to predict
11 TAVI prosthesis anchoring in raphe-type bicuspid aortic valve disease: the LIRA
12 plane. *EuroIntervention* 2020;**16**:259–61.
13
14

1 **FIGURES LEGEND**

2

3 Figure 1

4 Overview showing the main steps of the virtual insertion of a Venus A-valve in a patient
5 specific geometry derived from pre-operative CT, while aiming for a virtual implantation
6 depth identical to the actual one.

7 CT = computed tomography; 3D = three-dimensional; FEA = finite element analysis

8

9 Figure 2

10 Illustration of the division of the two-dimensional deformed device skirt into anatomical (top
11 panel) and apposition/malapposition (bottom panel) sections. This division is evidenced both
12 with a border line and with a color palette, as depicted in the legend.

13

14 Figure 3

15 (a) Correlation and (b) difference plots for obtained device measurements vs predicted device
16 measurements for all device levels.

17

18 Figure 4

19 Box and whiskers diagram showing predicted skirt malapposition for patients with none or
20 trace, mild and moderate PVL. Extreme values are presented as small circles (o).

21

22 Figure 5

23 Post-operative PVL grading (none or trace, mild and moderate) for the different types of
24 valve morphologies: TAV, BAV, BAV0 and BAV1.

25

26 Figure 6

27 Analysis of two cases of the cohort with different valve morphologies: TAV (total skirt
28 malapposition of 4.4%, PVL grade 0) and BAV1 (total skirt malapposition of 20.9%, PVL
29 grade 1). For each case, the following is shown: cross-section at the aortic annular plane in
30 the pre-operative CT, three-dimensional reconstruction of the valve (and its calcifications)
31 and distribution of the apposition/malapposition sections of the two-dimensional deformed
32 device skirt. For the BAV1 case, the red arrow indicates the raphe and the black arrow the
33 largest PVL channel.

34 CT = computed tomography; 3D = three-dimensional; 2D = two-dimensional

1

2 Figure 7

3 (a) Contribution of each anatomical section to the malapposition (mean, %) of the total skirt.

4 (b) Contribution of each anatomical section to the apposition (mean, %) for the apposed

5 section of the skirt. All these values are presented for the different types of valve

6 morphologies: TAV, BAV, BAV0 and BAV1.

7 TAV = tricuspid aortic valve; BAV = bicuspid aortic valve; BAV0 = type 0 bicuspid aortic

8 valve; BAV1 = type 1 bicuspid aortic valve

9

10

Table 1. Patient Characteristics.

	BAV type 0	BAV type 1	BAV	TAV	p Value
	n = 11	n = 15	n = 26	n = 17	
Age (yrs)	77.8±5.6	75.4±8.1	76.4±7.1	79.4±6.2	0.164
Male	5(45.5)	12(80.0)	17(65.4)	9(52.9)	0.528
Height (cm)	159.1±6.5	165.7±6.5	162.9±7.2	162.2±8.8	0.780
Weight (kg)	59.0±8.0	64.9±9.4	62.4±9.1	60.4±11.8	0.544
Body Mass Index (kg/m ²)	23.31±3.01	23.59±2.94	23.47±2.91	22.85±3.59	0.542
STS	5.29±3.12	5.15±2.56	5.21±2.75	8.33±5.95	0.124*
Echocardiography					
Left ventricular ejection fraction (%)	54.9±14.9	55.0±12.7	55.0±13.3	54.8±17.3	0.593*
Aortic valve area (cm ²)	0.53±0.21	0.66±0.15	0.60±0.19	0.62±0.21	0.726
Mean gradient (mmHg)	59.4±19.4	56.5±15.2	57.7±16.8	52.9±11.5	0.478*
Max velocity (m/s)	4.98±0.90	4.67±0.94	4.80±0.92	4.70±0.42	0.526*
Multi-slice computed tomography					
Max annulus diameter (mm)	27.4±3.5	29.6±3.0	28.7±3.4	27.4±3.2	0.240
Min annulus diameter (mm)	21.7±3.5	22.7±3.4	22.3±3.4	21.1±2.3	0.209
Mean annulus diameter (mm)	24.5±3.4	26.2±3.1	25.5±3.3	24.3±2.7	0.212
Perimeter derived diameter (mm)	24.7±3.3	26.5±3.1	25.8±3.3	24.7±3.0	0.312
Area derived diameter (mm)	24.3±3.3	26.0±3.1	25.3±3.2	24.2±2.9	0.285
Calcium volume (mm ³)	1210.7±778.0	1213.5±676.6	1212.4±701.6	781.8±576.6	0.094
Procedural characteristics					
Implanted depth (mm)	6.2±3.3	6.1±4.2	6.1±3.7	7.4±3.1	0.236
Device size					
23mm	3(27.3)	1(6.7)	4(15.4)	1(5.9)	0.586
26mm	7(63.6)	8(53.3)	15(57.7)	11(64.7)	
29mm	0(0.0)	5(33.3)	5(19.2)	2(11.8)	

32mm	1(9.1)	1(6.7)	2(7.7)	3(17.6)	
Sizing index§	1.05±0.11	1.03±0.09	1.04±0.09	1.11±0.07	0.018
Postprocedural outcomes					
Mortality	0(0.0)	0(0.0)	0(0.0)	0(0.0)	-
Stroke	0(0.0)	0(0.0)	0(0.0)	0(0.0)	-
MI	0(0.0)	0(0.0)	0(0.0)	0(0.0)	-
PVL III/IV	3(27.3)	2(13.3)	5(19.2)	1(5.9)	0.376
Pacemaker Implantation	1(9.1)	1(6.7)	2(7.7)	2(11.8)	1.000

§Sizing index = (device size) / (perimeter-based diameter).

* Mann-Whitney U test was used.

Data are presented as no. (%) and mean ± SD.

BAV, bicuspid aortic valve; MI, myocardial infarction; PVL, paravalvular leakage; TAV, tricuspid aortic valve.

Table 2. Mean (\pm SD) difference between the measurements of the observed (post-operative) and the simulated (model) device and respective R-squared coefficient for the different levels of the device.

Measurement	Mean Difference (Post-op - Model)	R²
Dmax (mm)	0.10 \pm 1.42	0.90
Dmin (mm)	0.06 \pm 1.55	0.90
Perimeter (mm)	0.34 \pm 3.25	0.95
Area (mm ²)	0.96 \pm 41.14	0.96

Table 3. Overview of sealing analysis data for the different valve morphologies

	BAV type 0 n = 11	BAV type 1 n = 15	BAV n = 26	TAV n = 17	p Value
LVOT					
Apposed area (mm ²)	72.4±68.4	133.1±190.4	107.4±152.0	157.4±135.7	0.106*
Malapposed area (mm ²)	47.8±87.0	81.6±126.4	67.3±110.7	52.0±79.9	0.980*
Interleaflet triangles					
Apposed area (mm ²)	146.4±95.2	123.8±75.5	133.4±83.4	175.1±73.4	0.100
Malapposed area (mm ²)	146.1±60.1	100.5±45.7	119.8±56.1	65.5±36.4	0.001
Leaflets					
Apposed area (mm ²)	590.6±84.2	628.3±191.8	612.4±154.3	611.5±193.6	0.987
Malapposed area (mm ²)	69.1±52.0	73.8±30.6	71.8±40.1	56.8±30.1	0.195
Malapposition in total skirt (%)	24.1±10.6	21.6±10.5	22.7±10.5	15.5±9.8	0.030
Malapposition in LVOT (%)	3.6±5.4	6.0±8.2	4.9±7.1	4.6±7.1	0.960*
Malapposition in Interleaflet triangles (%)	14.0±6.4	9.0±4.0	11.1±5.7	5.8±2.8	0.001*
Malapposition in Leaflet (%)	6.5±4.9	6.7±3.1	6.6±3.8	5.2±2.9	0.200
Apposition in total skirt (%)	75.9±10.6	78.4±10.6	77.3±10.5	84.5±9.8	0.030
Apposition contribution LVOT (%)	8.4±7.9	14.2±19.8	11.7±15.9	17.0±16.0	0.124*
Apposition contribution Interleaflet triangles (%)	16.8±8.7	13.1±7.0	14.7±7.9	18.0±4.9	0.172*
Apposition contribution Leaflet (%)	74.8±14.0	72.7±20.0	73.6±17.4	64.9±17.6	0.120


* Mann-Whitney U test was used.

Data are presented as mean ± SD.


BAV, bicuspid aortic valve; LVOT, left ventricular outflow tract; TAV, tricuspid aortic valve.

Patient CT scans

pre-operative




post-operative




3D
reconstruction

Segmentation



Simulated
device


FEA



match
implantation
depth


2D skirt plot

3D device skirt




Unroll skirt


Classify by anatomical section




Classify by apposition/malapposition




(a)





(b)



Malapposed skirt (%)




S. boydii
 S. mitsu
 S. mitsu



TAV


pre-operative CT scan



3D reconstruction



2D skirt




BAV1


pre-operative CT scan



3D reconstruction





2D skirt



(a)

LVTI
 Intermediate Triangles
 Leathers

**(b)**